PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Flexi Communications

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kyrgyz Pharmaceutical Company Pharmaco Group Enters the Central Asian Markets - Kyrgyz pharmaceutical company Pharmaco Group enters the Central Asian markets The strategic goal of Pharmaco Group is to boost its export potential in Central Asia (Uzbekistan, Tajikistan and Afghanistan). By the end of 2009 the facility will launch
Kyrgyz Pharmaceutical Company Pharmaco Group Enters the Central Asian Markets

 

NewswireToday - /newswire/ - Bishkek, Kazakhstan, 2009/05/02 - Kyrgyz pharmaceutical company Pharmaco Group enters the Central Asian markets The strategic goal of Pharmaco Group is to boost its export potential in Central Asia (Uzbekistan, Tajikistan and Afghanistan). By the end of 2009 the facility will launch.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

At the international exhibition "Healthcare – TIHE 2009" that took place in Tashkent provisional agreements were made between the domestic manufacturer Pharmaco Group, and regional distributors, the company informs.

"The medical forum enabled the company to show itself to be the new Central Asian manufacturer of high quality medications. The level and size of the exhibition – which resulted in hundreds of contracts being signed each day - allowed us to reach all of our set goals. We carried out the analysis of Uzbekistan’s pharmaceutical market, met the leading medical professionals and representatives of distributing companies. Presently we are to choose an exclusive partner to represent us in Uzbekistan, register and distribute Pharmaco Group products in the republic", says Alexander Karpov, Pharmaco Group General Director, as quoted by the company press office.

According to A. Karpov, “Pharmaco Group products generated considerable interest among distributors and doctors due to their good value for money; particular attention was drawn to the antibiotic group manufactured at the Bishkek facility, particularly cefazolin, which currently is a sought-for medication in the Uzbek pharmaceutical market”.

“Considering the fact that Uzbekistan is the most densely populated country in Central Asia, the pharmaceutical market of the republic has very promising prospects for Pharmaco Group. On the other hand, as it turned out, the neighboring state was in need of generic medications. We have already begun working on forming the product mix proposal,” notes the head of the company, as quoted by the press office.

Pharmaco Group is a pharmaceutical plant located in Bishkek, the Kyrgyz capital. Its annual output equals 500 million pills, 100 million capsules and 12 million vials of antibiotic powders. These medications are used in gastroenterology, dermatology, gynecology, urology, rheumatology, cardiology and pediatrics.

The strategic goal of Pharmaco Group is to boost its export potential in Central Asia (Uzbekistan, Tajikistan and Afghanistan). By the end of 2009 the facility will launch production of six antituberculous drugs - capreomicin, pyrazinamide, cycloserine, paraaminosalicylic acid, protionamide and ofloxacin. In the nearest future Pharmaco Group is planning to introduce antidiabetic medications such as gliclazide and metformin to its product portfolio.

"Healthcare – TIHE 2009" is the annual Central Asian exhibition project. In 2009 it was held for the fourteenth time and included four specialized medical exhibitions devoted to healthcare, pharmaceutical industry, aesthetic medicine and dentistry. Companies from Russia, China, USA, Great Britain, Switzerland, Turkey South Korea and the Central Asian countries are among the participants and attendees of the event.

MGN Analysis
Pharmaco Group, a pharmaceutical manufacture, which began operating in 2008 and is headquartered in Bishkek Kyrgyzstan, announced that it is expanding to other Central Asia markets. The company, which produces various generic and specialty drugs in pill, capsule and vial form, has been aggressively growing in the Kyrgyz market and is now seeking to expand in neighboring markets. The pharmaceutical market in Kyrgyzstan and neighbor countries is estimated in excess of $1.0 bln UDS. MGN anticipated Pharmaco’s ability to grow to external markets as the company is known to produce high quality pharmaceutical products in Kyrgyzstan. MGN believes that this is just the first in a series of success stories to come from this company. We anticipate that Pharmaco Group will boldly compete with other pharmacy companies in Central Asia and is a highlight in the Kyrgyz business community.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Flexi Communications

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kyrgyz Pharmaceutical Company Pharmaco Group Enters the Central Asian Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Elmira Mamytbekova - FlexiCommunications.com 
+996 312 62 25 84 Sophya.balakina[.]flexicommunications.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Flexi Communications securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Flexi Communications / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)